ProJenX is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Their lead candidate, prosetin, is a first-in-class MAP4 kinase (MAP4K) inhibitor designed to penetrate the blood-brain barrier effectively, allowing it to target motor neurons directly. This unique approach is grounded in extensive research collaboration with Columbia University, where scientists have created patient-derived models of ALS. These models have been instrumental in understanding the disease's impact on motor neurons and in optimizing prosetin for therapeutic use.

The development of prosetin is particularly significant as it addresses a common challenge in ALS treatment: the inability of most drugs to cross the blood-brain barrier. ProJenX's research indicates that prosetin can mitigate endoplasmic reticulum (ER) stress, a well-documented factor in various ALS subtypes, thereby protecting motor neurons from degeneration. In addition to ALS, ProJenX is exploring the potential of MAP4K inhibition in treating other neurodegenerative disorders, highlighting their commitment to advancing therapeutic strategies for a range of debilitating brain diseases.

United States

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines. 

ProJenX

Company Details